Modulation of Tenoxicam release from hydrophilic matrix: modulator membrane versus rate-controlling membrane.
This paper describes the preparation of two layered device comprising of tenoxicam containing layer and a drug free membrane layer based on Geomatrix Technology. Our device based on bilaminated films which produced by a casting/solvent evaporation technique. The drug-hydroxypropyl methylcellulose (HPMC) layer was covered by drug free membrane layer composed of a mixture of different ratios of HPMC and ethyl cellulose (EC). The prepared devices were evaluated for thickness, weight, drug content uniformity, water absorption capacity and in-vitro drug release. The films were also evaluated for appearance, smoothness and transparency. The influence of drug free membrane layer composition and thickness on the drug release pattern was studied on 12 devices (D1 to D12). The results indicate that, the release of drug from HPMC matrixes without the drug free membrane layer was fast and follows diffusion controlled mechanism. The release of drug from the devices D1, D4, D9 and D12 follow the same mechanism, while the release of drug from other devices become linear with time (zero order) and extended for long time especially when thickness and the ratio of EC was increased in the drug free membrane layer. From this study it is concluded that, changing the geometry of drug layer by addition of drug free membrane layer and changing its composition and thickness plays an important role in determining whether the drug free membrane layer is rate-controlling or modulator membrane. Hence it can facilitate the development of different pharmaceutical products with different release pattern.
El-Nabarawi
Mohamed Ahmed
MA
Department of Pharmaceutics and Industrial Pharmacy, Cairo University, 11562 Cairo, Egypt. nabrwima@hotmail.com
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000737:chemistry; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004337:Drug Carriers; D016503:Drug Delivery Systems; D007700:Kinetics; D007785:Lactose / Q000031:analogs & derivatives; D008567:Membranes, Artificial; D008747:Methylcellulose / Q000031:analogs & derivatives; D008855:Microscopy, Electron, Scanning; D010078:Oxazines; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D013499:Surface Properties
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D008567:Membranes, Artificial; D010078:Oxazines; D010894:Piroxicam; D008747:Methylcellulose; C071191:MK 458; D007785:Lactose; C032801:tenoxicam